Kruger, Ryan G.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 1,786

The promise and peril of chemical probes

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology

Click Chemistry and ApplicationsComputational Drug Discovery Methods

Cited by 839

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology

Cancer-related gene regulationProtein Degradation and Inhibitors

Cited by 569

Abstract 2994: Discovery of selective, noncovalent small molecule inhibitors of DNMT1 as an alternative to traditional DNA hypomethylating agents

Pappalardi, M. B., Cockerill, M., Handler, J. L., Stowell, A., Keenan, K., Sherk, C. S., Minthorn, E. A., McHugh, C. F., Burt, C., Wong, K., et al. (2018) · Cancer Research

Epigenetics and DNA MethylationHistone Deacetylase Inhibitors Research

Cited by 9